

**Peripheral blood DNA methylation markers for the early
detection of colorectal carcinoma in the Egyptian
population: a multicenter study**

By.Rania Mohammed Leithy Ibrahim

MSc Hepatology,Gastroenterology and Infectious endemic diseases

A thesis submitted in partial fulfillment of MD degree of
Hepatology,Gastroenterology and Infectious endemic diseases

Faculty of Medicine -Cairo University

Supervisors

Dr. Ashraf Omar Abdel Aziz

Professor of Hepatology,Gastroenterology and Infectious endemic diseases

Faculty of Medicine

Cairo University

Dr. Ayman Rashad Amer

Professor of Hepatology,Gastroenterology and Infectious endemic diseases

Faculty of Medicine

Cairo University

Dr. Hany Mofeed Shehab

Assistant Professor of Hepatology,Gastroenterology and Infectious
endemic diseases

Faculty of Medicine

Cairo University

Dr. Dina Sabry Abdel Fatah

Professor of Biochemistry

Faculty of Medicine

Cairo University, 2015

ACKNOWLEDGEMENT

First of all, thanks to ALLAH for his grace and mercy for giving me the effort and strength to complete this work,

*I was fortunate enough to carry out this work under the supervision of **Prof. Dr. Ashraf Omar Abd El-Aziz**, Professor of Tropical Medicine; Cairo University. He chose me for this work and his care, support and invaluable experience were of much guidance to me.*

*I cannot express my deepest gratitude and appreciation to **Prof. Dr. Ayman Rashad Amer**, Professor of Tropical Medicine for his support, effort and guidance during all the steps done through this work. He gave me much of his experience, meticulous invaluable advice and support that can't be expressed in words*

*Words will never be able to express my deepest gratitude and appreciation to **DR. Hany Mofeed Shehab**, Assistant Professor of Endemic Medicine, Cairo University, for his generous help and goodness, meticulous revisions all through the work. He gave me much of his time, experience and support. His valuable comments, efforts and collaboration were the causes to complete this work properly*

*I am greatly honored to express my deep gratitude and faithfulness to **PROF. DR. Dina Sabry Abdel Fatah**, Professor of Biochemistry, Faculty of Medicine, Cairo University; she carried out the practical work of cases with devoted comprehensive technical help throughout the work, meticulous invaluable advice and support that cannot be expressed in words.*

I would like to thank all my staff members of the Endemic Medicine Department, Cairo University.

Last but not least, allow me to send my deepest gratitude, appreciation & sincere thanks to my family for their sacrifice in order to make me stand where I am today.

LIST OF CONTENT

List of abbreviations.....	I
List of figures.....	II
List of Tables.....	III
Abstract.....	IV
Introduction.....	1
Aim of The work.....	3
Review of literature.....	4
<u>Chapter I</u> : Introduction.....	4
<u>Chapter II</u> : Premalignant colorectal lesions.....	12
<u>Chapter III</u> : CRC screening and surveillance.....	18
<u>Chapter IV</u> : molecular basis of colorectal cancer.....	32
Patients and Methods.....	59
Results.....	68
Discussion.....	77
Summary and Conclusions.....	83
Recommendations.....	86
References.....	87

.....الملخص العربي

LIST OF ABBREVIATIONS

AJCC	American Joint Committee on Cancer
APC	Adenomatous Polyposis Coli Syndromes
CD	Crohn's Disease
CDH1	E-cadherin
CDH13	Cadherin 13
CDKN2A/p14	Cyclin-dependent kinase inhibitor 2A
CDKN2A/p16	Cyclin-dependent kinase inhibitor 2A
CEA	Carcino-Embryonic Antigen
CHPRE	Congenital Hypertrophy of the Pigmented Retinal Epithelium
CI	Chromosomal Instability
CIMP	CpG Island Methylator Phenotype
CPG	Cytosine-Phosphate-Guanine
CRC	Colorectal Cancer
CTC	CT-Colonography
DCBE	Double Contrast Barium Enema
EGFR	Epidermal Growth Factor Receptor
FAP	Familial Adenomatous Polyposis
FITs	Fecal Immunochemical Tests

FOBTs	Fecal Occult Blood Tests
FS	Flexible Sigmoidoscopy
KRAS	Kirstein Rat Sarcoma
LOH	Loss Of Heterozygosity
HLTF	Helicase-like transcription factor
HNPCC	Hereditary Non Polyposis Colorectal Cancer
IBD	Inflammatory Bowel Disease
MAPK	Mitogen-Activated Protein Kinase
MI	Microsatellite Instability
MGMT	O-6-methylguanine-DNA methyltransferase
MMR	Mismatch Repair genes
NCI	National Cancer Institute
NHL	Non Hodgkin lymphoma
PI3KCA	Phosphatidylinositol 3-kinase catalytic subunit
PJS	Peutz-Jeghers Syndrome
RASSF1A	Ras association domain family 1 (isoform A)
RUNX3	Runt-related transcription factor 3
TGF-β	Transforming Growth factor- β
TSGMP	Tumor Suppressor Gene Methylator Phenotype

List of Abbreviations

UC	Ulcerative Colitis
VEGF	Vascular Endothelial Growth Factor

LIST OF FIGURES

No.	Figure	Page
Figure (1)	Correlation between CRC progression and the accumulation of genetic alterations	34
Figure (2)	Genetic instability pathways that drive colon neoplasias	36
Figure (3)	Colon cancer can be diagnosed in surgically dissected biopsy (a), in stool (b) or in blood samples (c) of CRC patients	50

LIST OF TABLES

No.	Table	Page
Table (1)	Summary of Major Risk Factors for Colorectal Cancer	7
Table (2)	the protective factors for colorectal cancer risk	8
Table (3)	Modified Duke Staging System	10
Table (4)	TNM Staging System	11
Table (5)	risk stratification and methods of screening and Surveillance:	19
Table (6)	The following options are recommended for colorectal cancer screening in men and women aged 50 and older at average risk	20
Table (7)	Recommendations for individuals with family history of CRC or adenomatous polyps	28
Table (8)	Recommendations for individuals with genetic cancer syndromes	28
Table(9)	Surveillance recommendations for individuals with significant personal history of colorectal neoplasia	29
Table(10)	Summary of the main differences in the recommendations for colorectal cancer surveillance programs in inflammatory bowel disease patients	31
Table(11)	Some examples of genes frequently methylated and silenced in CRC	47
Table(12)	Some examples of DNA methylation biomarkers for CRC diagnosis, progression, prognosis and treatment	48
Table(13)	Shows the primers for the studied genes	62
Table(14)	PCR master mix components	63
Table(15)	PCR thermal profile	63
Table(16)	Running condition for PCR	64

Table (17)	Demographic features of the studied patients	68
Table (18)	Frequency of IBD, familial polyposis and family history of CRC in the studied groups	69
Table (19)	Clinical presentations of the studied patients; number (%)	69
Table (20)	Characteristics of the lesion	70
Table (21)	Results of methylation of different biomarkers	72
Table (22)	Performance of the biomarkers	73
Table (23)	Sensitivity and specificity of biomarkers	75
Table (24)	Number of positive cases (methylation level for each marker) in the studied groups	76
Table (25)	Senistivity of biomarkers regarding location, age and sex	76

ABSTRACT

BACKGROUND: DNA methylation is one of the most important epigenetic mechanisms, which denotes the addition of a methyl group to DNA. Aberrant promoter demethylation is usually associated with overexpression of genes that might participate in pathogenesis of many diseases

AIM OF THE WORK: to evaluate serum *ALX4*, *SEPT9*, *CDH4* and *CDKN2B/P15* and their candidacy as novel noninvasive markers, in CRC among Egyptian patients.

METHODS: A whole blood sample (10cc) will be collected in an EDTA-containing vacutainer tube and stored at 4C for a maximum of 24 hours. Samples will be delivered within this period to the molecular biochemistry lab for removal of the Buffy coat, DNA extraction and analysis. The molecular biologist will assess all samples in a blinded fashion.

RESULTS: *ALX4* shows the highest sensitivity (97.6%) and specificity (99.3%) with cut-off of 0.315 µg/L Followed by *CDKN2B/P15* (sensitivity=96.1% and specificity=97.8%) with cut-off of 0.412 µg/L and *SEPT9* (sensitivity=87.4% and specificity=98.5%) with cut-off of 0.461 µg/L while *CDH4* shows the least sensitivity=75.6% and specificity=70.1% with cut-off of 0.330 µg/L.

CONCLUSION: *ALX4*, *SEPT9*, *CDH4* and *CDKN2B/P15* can be useful in high prediction of colorectal carcinoma with high sensitivity and specificity.

Keywords:

Peripheral blood DNA methylation markers for the early detection of colorectal carcinoma in the Egyptian

INTRODUCTION

Colorectal cancer (CRC), including anal, is the 3rd most common cancer in the world. It is the 4th most common cause of cancer death worldwide (*Ferlay, et al., 2010*).

Globally, the incidence of CRC varies over 10-fold. The highest incidence rates are in Australia and New Zealand, Europe and North America, and the lowest rates are found in Africa and South-Central Asia. These geographic differences appear to be attributable to differences in dietary and environmental exposures that are imposed upon a background of genetically determined susceptibility (*Jemal, et al 2011*).

In Egypt, CRC represents about 4% of total cancers in both sexes. Variation in environmental risk factors particularly the higher content of dietary fibers more physical activity and lower obesity rates can explain different incidence rates between Egypt and the western countries with higher incidence in the western countries (*Zeeneldin, et al 2012*).

Early diagnosis of CRC potentially reduces the mortality of this disease (*Walsh & Terdiman, 2003*). Although colonoscopic screening for CRC is currently the most reliable diagnostic tool, its cost and invasive nature limit its use. Thus, there is a pressing need for novel, non-invasive, highly sensitive biomarkers to improve the detection of CRC (*Yang et al., 2013*) but this is hindered by their cost.

In the last few years, there has been increasing interest in using blood samples to measure DNA methylation in cancer cases and controls (*Cho et al., 2010*).

DNA methylation is one of the most important epigenetic mechanisms, which denotes the addition of a methyl group to DNA. It is widespread in the human genome and mainly occurs at cytosine adjacent to guanine (CpG dinucleotides) (*Cokus et al., 2008*).

DNA methylation in gene promoter regions often results in long-term silencing of gene expression (*Jones, 2012*). Meanwhile, aberrant promoter demethylation is usually associated with overexpression of genes that might participate in pathogenesis of many diseases (*Qian et al., 2015*). Previous studies demonstrated that aberrant demethylation in the promoter region of genes occurs in many diseases and may be used as a biomarker (*Zhang et al., 2015*).

No solitary biomarker is considered adequately sensitive and specific for CRC screening due to the substantial heterogeneity of colon cancer. A combination of markers spanning multisignaling pathways leading to colon cancer is needed for optimal sensitivity. The “multiple markers,” which detect known genetic and epigenetic alterations of colon cancer, will be more effective and beneficial than a single one for early detection and prediction of patient outcome. Identification of “universal methylation markers,” if they are highly specific and sensitive for common tumors and in many cases, would be useful for the detection of human cancer (*Esteller et al., 2001*).

AIM OF THE WORK

The aim of the present study is to evaluate methylation level of serum *ALX4*, *SEPT9*, *CDH4* and *CDKN2B/P15* genes as novel non-invasive markers in CRC among Egyptian patients.